Your browser doesn't support javascript.
loading
Disease quiescence in endophthalmitis patients treated with anti-VEGF injections for retinal pathologies.
Vofo, Brice Nguedia; Saada, Majd; Rivera, Antonio; Cohen, Sigalit; Jaouni, Tareq; Khateb, Samer.
Afiliação
  • Vofo BN; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel.
  • Saada M; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel.
  • Rivera A; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel.
  • Cohen S; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel.
  • Jaouni T; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel. drtareqj@yahoo.com.
  • Khateb S; Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, POB 12000, Israel.
BMC Ophthalmol ; 24(1): 73, 2024 Feb 16.
Article em En | MEDLINE | ID: mdl-38365648
ABSTRACT

BACKGROUND:

The most feared complication of intravitreal injections is the development of endophthalmitis, which could lead to irreversible visual loss. The aim of this study was to characterize the clinical profiles, causative pathogens, and clinical outcome of patients post-endophthalmitis.

METHODS:

Retrospective, single center case series study. Clinical records, causative pathogens and management of all cases of endophthalmitis post intravitreal anti-vascular endothelial growth factor (VEGF) injections recorded between January 1st, 2006 and May 30th, 2022; were retrieved. The visual and anatomic changes prior to the episode of endophthalmitis and up to 2 years post-treatment were compared.

RESULTS:

Eleven post-injection endophthalmitis eyes of 10 patients (n = 3 females; 30%) were recruited at mean age of 64.5 ± 20.4 years. The median last recorded BCVA, up to 3 months prior to the episode of endophthalmitis was 60 (Interquartile range (IQR) 55-75) ETDRS letters. Then, it dropped to 30 (IQR 0-57.5), 35 (IQR 0-52.5) and 35 (IQR 0-57.5) ETDRS letters at presentation, 6- and 12-months follow-up; respectively (p = 0.027, p = 0.017 and p = 0.012). However, at 24 months, the median BCVA returned to similar baseline values prior to the episode of endophthalmitis; BCVA 50 (IQR 0-60) ETDRS letters, p = 0.062. Interestingly, two eyes with neovascular age-related macular degeneration (NVAMD), 1 with myopic choroidal neovascularization (CNV) and 1 with retinal vein occlusion (RVO), experienced disease quiescence and did not require additional anti-VEGF injections up to 2 years of follow-up.

CONCLUSION:

This study demonstrates long-term recovery of vision loss due to endophthalmitis post anti-VEGF injections, regained up to 2 years later. It also indicates that disease quiescence post endophthalmitis may not only occur in eyes treated for NVAMD, but also with myopic CNV and RVO.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oclusão da Veia Retiniana / Endoftalmite / Neovascularização de Coroide Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: BMC Ophthalmol Assunto da revista: OFTALMOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oclusão da Veia Retiniana / Endoftalmite / Neovascularização de Coroide Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: BMC Ophthalmol Assunto da revista: OFTALMOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Israel